QBIO Stock Overview
A biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Q BioMed Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0001 |
52 Week High | US$0.041 |
52 Week Low | US$0.000001 |
Beta | 0 |
11 Month Change | 9,900.00% |
3 Month Change | 9,900.00% |
1 Year Change | -83.33% |
33 Year Change | -99.98% |
5 Year Change | -99.99% |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
QBIO | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 2.4% | 0.5% |
1Y | -83.3% | 15.6% | 30.7% |
Return vs Industry: QBIO underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: QBIO underperformed the US Market which returned 32.3% over the past year.
Price Volatility
QBIO volatility | |
---|---|
QBIO Average Weekly Movement | 6,285.1% |
Biotechs Industry Average Movement | 9.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: QBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QBIO's weekly volatility has decreased from 20792% to 6285% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | n/a | Denis Corin | www.qbiomed.com |
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer.
Q BioMed Inc. Fundamentals Summary
QBIO fundamental statistics | |
---|---|
Market cap | US$14.51k |
Earnings (TTM) | -US$1.91m |
Revenue (TTM) | US$209.29k |
0.0x
P/S Ratio0.0x
P/E RatioIs QBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QBIO income statement (TTM) | |
---|---|
Revenue | US$209.29k |
Cost of Revenue | US$221.90k |
Gross Profit | -US$12.60k |
Other Expenses | US$1.90m |
Earnings | -US$1.91m |
Last Reported Earnings
Feb 28, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did QBIO perform over the long term?
See historical performance and comparison